临床肝胆病杂志2011，Vol.27Issue(1)：86-88,3.
聚乙二醇干扰素α-2a/2b联合利巴韦林复治慢性丙型肝炎患者的疗效观察
Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C
朱研 1毛青 1张长江 1孙伟 1胡亚君 1谭朝霞 1王小红1
作者信息
- 1. 第三军医大学西南医院全军感染病研究所,重庆,400038
- 折叠
摘要
Abstract
Objective To assess the effectiveness and to investigate the influencing factors of pegylated interferon α-2a/2b(PEGIFNα-2a/2b) and ribavirin retreatment in patients with chronic hepatitis C(CHC) after initial course of IFN or PEG-IFNα-2a/2b plus ribavirin therapy.Methods A retrospective study was designed to analyze retreatment with IFN or PEG-IFNα-2a/2b plus ribavirin of 30 relapsed CHC patients.All of them received PEG-IFNα-2a at a dose of 180μg/week or PEG-IFNα-2b 1.5μg·kg-1·week-1 and ribavirin at a dose of 900mg/day for 24 or 48 weeks depending on the HCV genotype.The main parameter to evaluate the effectiveness was sustained virologic response(SVR) rate.The influences of HCV RNA load at the baseline, genotype and previous drug categories on response to IFN were analyzed.Results The SVR rate was 80％ for all the patients.The SVR rate of the patients with low viral loads(HCV RNA≤ 1 × 105copies/ml) was markedly higher than that of the patients with high viral loads(HCV RNA＞1 × 105copies/ml)( 94.4％ and 58.3％, P=0.026).The HCV genotype and previous drug categories did not affect the likelihood of SVR although this may be the result of the relatively small number of patients.Conclusion Relapse after previous IFN or PEGIFNα-2a/2b plus ribavirin therapy is associated with a strong probability of treatment success.Baseline serum HCV RNA load is a predictive parameter of SVR.关键词
肝炎,丙型,慢性/干扰素α-2a/利巴韦林Key words
hepatitis C/ chronic/ interferon alfa-2a/ Ribavirin分类
医药卫生引用本文复制引用
朱研,毛青,张长江,孙伟,胡亚君,谭朝霞,王小红..聚乙二醇干扰素α-2a/2b联合利巴韦林复治慢性丙型肝炎患者的疗效观察[J].临床肝胆病杂志,2011,27(1):86-88,3.
